Challenges in transfusion and the role of Thalidomide in E‐β‐Thalassemia—A case report
暂无分享,去创建一个
[1] M. Chandy,et al. Thalidomide in Patients with Transfusion-Dependent E-Beta Thalassemia Refractory to Hydroxyurea: A Single-Center Experience , 2020, Indian Journal of Hematology and Blood Transfusion.
[2] Sandip Shah,et al. Safety and effectiveness of thalidomide and hydroxyurea combination in β‐thalassaemia intermedia and major: a retrospective pilot study , 2019, British journal of haematology.
[3] M. Porteus,et al. Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β-globin locus. , 2018, Blood.
[4] E. Angelucci,et al. Dramatic erythroid response to low‐dose thalidomide in two patients with transfusion independent thalassemia and severe post‐transfusional alloimmune hemolysis , 2015, American journal of hematology.
[5] S. Ferdowsi,et al. RBC alloimmunization and double alloantibodies in thalassemic patients , 2015, Hematology.
[6] M. Shahjahani,et al. Evaluation of Novel Fetal Hemoglobin Inducer Drugs in Treatment of β-Hemoglobinopathy Disorders , 2013, International journal of hematology-oncology and stem cell research.
[7] S. Masoud,et al. Evaluation the Effect of Thalidomide and Sodium Butyrate on Cord Blood Stem Cell Differentiation Induction to Erythroid Lineage , 2011 .
[8] G. Masera,et al. Optimal response to thalidomide in a patient with thalassaemia major resistant to conventional therapy. , 2010, Blood transfusion = Trasfusione del sangue.
[9] S. Al-Shemmari,et al. RBC alloimmunization and autoimmunization among transfusion‐dependent Arab thalassemia patients , 2003, Transfusion.
[10] S. Rajkumar,et al. Management of thalidomide toxicity. , 2003, The journal of supportive oncology.